Evaluating Early Macrolide Therapy in Pediatric Campylobacter Enterocolitis: A Comparative Study

Area of Science:

• Pediatric Infectious Diseases
• Microbiology
• Clinical Pharmacology

Background:

• Limited evidence supports azithromycin as first-line treatment for pediatric Campylobacter enterocolitis.
• Efficacy of alternative macrolides in this context is understudied.
• Need for evaluating early macrolide therapy initiation.

Purpose of the Study:

• To assess the effectiveness of early macrolide antibiotic therapy (within 3 days of symptom onset) in pediatric Campylobacter enterocolitis.
• To compare outcomes between azithromycin, clarithromycin, and no macrolide treatment.
• To evaluate macrolide therapy's impact on clinical resolution and hospitalization duration.

Main Methods:

• Randomized controlled trial comparing azithromycin and clarithromycin in pediatric patients.
• Retrospective cohort of pediatric patients who did not receive macrolide antibiotics for comparison.
• Enrollment of patients under 19 with newly diagnosed Campylobacter enterocolitis.

Main Results:

• Early macrolide therapy (27 patients) was associated with reduced hospital stay (3.8 vs. 4.5 days) compared to non-macrolide treatment (37 patients).
• Significant reductions in diarrhea duration (1.8 vs. 3.4 days, p < 0.001) and fever duration (1.1 vs. 2.8 days, p < 0.001) were observed with early macrolide use.
• No significant difference in vomiting duration was noted (p = 0.061).

Conclusions:

• Early macrolide antibiotic initiation in children with Campylobacter enterocolitis accelerates clinical resolution.
• Treatment shortens hospitalization by hastening the resolution of diarrhea, fever, and abdominal pain.
• Findings support the use of early macrolide therapy for pediatric Campylobacter enterocolitis.